Trial Profile
Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- 08 Nov 2016 Status changed from recruiting to discontinued due lack of enrollment.
- 24 Jul 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
- 14 May 2011 New trial record